College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA.
J Am Pharm Assoc (2003). 2013 Jan-Feb;53(1):39-45. doi: 10.1331/JAPhA.2013.12038.
To assess patients' information needs regarding drug-drug interactions (DDIs) to inform patient DDI education resources.
Cross-sectional study.
Online (United States in May 2011).
Registered users of an online medication monitoring service (MediGuard).
Online questionnaire.
Participants' information needs regarding DDIs and perceived importance of questions related to detecting and preventing harm from DDIs.
Characteristics of the 100 surveyed participants were as follows: 57% women, 88% white, 96% non-Hispanic, 71% retired, mean (±SD) age 65.2 ± 9.7 years (range 35-86). The number of prescription medications ranged from 2 to 22 (median 7) and the number of over-the-counter (OTC) medications from 1 to 10 (4). The most common concerns cited by participants were identification of interacting medications, seriousness of DDIs, interactions with OTC medications, interactions with foods, exacerbating comorbidities, short- and long-term adverse effects, signs and frequency of DDIs, and how to minimize adverse effects. Statistically significant differences based on gender, number of prescriptions, and number of OTC medications were observed in rankings of the importance of some DDI questions ( P < 0.05).
Patient-centered DDI education programs should consider addressing the seriousness of DDIs, the effect of DDIs on comorbidities, and interactions with OTC medications and foods and determining methods for identifying, minimizing, and managing DDIs.
评估患者对药物相互作用(DDI)的信息需求,以为患者 DDI 教育资源提供信息。
横断面研究。
在线(2011 年 5 月,美国)。
在线药物监测服务(MediGuard)的注册用户。
在线问卷调查。
参与者对 DDI 的信息需求以及对检测和预防 DDI 危害相关问题的重要性的感知。
调查的 100 名参与者的特征如下:57%为女性,88%为白人,96%为非西班牙裔,71%已退休,平均(±SD)年龄 65.2 ± 9.7 岁(范围 35-86)。处方药的数量从 2 到 22 种(中位数为 7),非处方药的数量从 1 到 10 种(中位数为 4)。参与者最常提到的关注问题是识别相互作用的药物、DDI 的严重程度、与 OTC 药物的相互作用、与食物的相互作用、加重合并症、短期和长期的不良反应、DDI 的迹象和频率,以及如何最大限度地减少不良反应。根据性别、处方数量和非处方药数量,一些 DDI 问题的重要性排名存在统计学差异(P < 0.05)。
以患者为中心的 DDI 教育计划应考虑解决 DDI 的严重程度、DDI 对合并症的影响以及与 OTC 药物和食物的相互作用,并确定识别、最小化和管理 DDI 的方法。